Dorzolamide HCl and Timolol Maleate Ophthalmic Solution
Defective Container: Firm received multiple complaints of broken cap spikes and undeliverable drops.
Yes — there is an active recall. 14 ongoing FDA recalls mention Timolol (34 total). Check the affected lots below.
Most common reason: Packaging defect (13 of these recalls)
Recalls are matched by product description. A recall usually affects specific lots, not every package of Timolol. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.
Defective Container: Firm received multiple complaints of broken cap spikes and undeliverable drops.
Lack of Assurance of Sterility
Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns
Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.
Lack of Assurance of Sterility
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
Defective Container: patients are unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Defective container; yellow colored spike from cap lodged in the nozzle
Defective Container: yellow-colored spike from cap lodged in the nozzle. Firm received several complaints from customers.
Lack of Assurance of Sterility: Out of specification for volume and compromised container closure.
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Failed Stability Specifications: Out of specification for weight loss at the 18-month stability timepoint and projected weight loss of 21.1% at shelf life.
Subpotent Drug: The batches contain less than 90% of the labeled amount of latanoprost.
CGMP Deviations:
Failed Impurities/Degradation Specifications: Identification of an unknown impurity at the 12-month stability point.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Labeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had the outer carton for Timolol Maleate Sterile Ophthalmic solution USP 0.5%, 5ml but the bottle inside was Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml.
Labeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had the outer carton for Timolol Maleate Sterile Ophthalmic solution USP 0.5%, 5ml but the bottle inside was Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml.
Subpotent Drug
Subpotent Drug
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.